sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com


Summary of Product Characteristics last updated on the eMC: 24/01/2011
SPC Maalox Plus Tablets


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Maalox Plus Tablets


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Aluminium hydroxide gel (dried)

Magnesium hydroxide

Simeticone

200mg

200mg

25mg


Go to top of the page
3. PHARMACEUTICAL FORM

Tablet.

Bi-layered white and yellow tablets, 16mm in diameter, with 'Maalox' embossed on one side.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

The symptomatic relief of:

a. Dyspepsia

b. Heartburn

c. Flatulence


Go to top of the page
4.2 Posology and method of administration

Route of administration: Oral

Adults (including elderly persons): 1-2 tablets well chewed, four times a day, taken twenty minutes to one hour after meals and at bedtime, or as required.

Children: Not recommended


Go to top of the page
4.3 Contraindications

Should not be used in patients who are severely debilitated or suffering from kidney failure.

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.


Go to top of the page
4.4 Special warnings and precautions for use

In patients with renal impairment, plasma levels of both aluminium and magnesium increase. In these patients, a long-term exposure to high doses of aluminium and magnesium salts may lead to dementia, microcytic anemia.

Aluminum hydroxide may be unsafe in patients with porphyria undergoing hemodialysis.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Maalox Plus should not be taken simultaneously with other medicines as they may interfere with their absorption if taken within 1 hour.

Aluminum hydroxide and citrates may result in increased aluminum levels, especially in patients with renal impairment.


Go to top of the page
4.6 Pregnancy and lactation

The safety of Maalox Plus Tablets in pregnancy has not been established..

Magnesium is considered as compatible with lactation


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

Gastrointestinal side effects are uncommon.


Go to top of the page
4.9 Overdose

Serious symptoms are unlikely following overdosage.

Treatment of magnesium overdose: consider administration of IV Calcium Gluconate, rehydration and forced diuresis. In case of renal deficiency, haemodialysis or peritoneal dialysis is necessary.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Dried aluminium hydroxide gel - antacid

Magnesium hydroxide - antacid

Simeticone - Antifoaming agent/antiflatulent

The antacids are balanced such that gastrointestinal side effects (constipation and diarrhoea) are minimal.


Go to top of the page
5.2 Pharmacokinetic properties

None stated


Go to top of the page
5.3 Preclinical safety data

None stated


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Swiss Cream flavour

Lemon flavour

Magnesium stearate

Talc

Citric acid, anhydrous

Glucose, anhydrous

Saccharin sodium

Sorbitol (E420)

Sorbitol liquid non-crystallising (E420)

Iron oxide yellow (E172)

Pregelatinised starch (Maize starch)

Maize starch

Sucrose

Mannitol (E421)


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

36 months


Go to top of the page
6.4 Special precautions for storage

Store below 30oC


Go to top of the page
6.5 Nature and contents of container

Plastic/aluminium strip packs packed in cardboard boxes

Packs of 40 tablets are available


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Sanofi-aventis

One Onslow Street

Guildford

Surrey

GU1 4YS

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 04425/0177


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

23 January 2009


Go to top of the page
10. DATE OF REVISION OF THE TEXT

10 January 2011


Go to top of the page
LEGAL STATUS
GSL



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/14778/SPC/


Active Ingredients/Generics

 
   aluminium hydroxide gel
   simeticone
   magnesium hydroxide